Effect of P53 expression on double-expressor lymphoma and characteristics of DLBCL co-expressing P53 and MYC: Clinical, pathological, and biological insights

Asian J Surg. 2024 Jun;47(6):2852-2855. doi: 10.1016/j.asjsur.2024.02.008. Epub 2024 Feb 26.

Authors

Yi-Zhuo Chen¹, Jin-Ling Bo¹, Shu-Ling Hou²

Affiliations

¹ Department of Lymphoid Oncology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
² Department of Lymphoid Oncology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China. Electronic address: csxtyhsl67@126.com.

PMID: 38408882
DOI: 10.1016/j.asjsur.2024.02.008

No abstract available

Keywords: Diffuse; Double-expressor lymphoma; Large B-Cell; Lymphoma; P53 protein; Prognosis.

Publication types

Letter

MeSH terms

Adult
Aged
Female
Humans
Lymphoma, Large B-Cell, Diffuse* / genetics
Lymphoma, Large B-Cell, Diffuse* / pathology
Male
Middle Aged
Proto-Oncogene Proteins c-myc* / genetics
Proto-Oncogene Proteins c-myc* / metabolism
Tumor Suppressor Protein p53* / genetics
Tumor Suppressor Protein p53* / metabolism

Substances

Tumor Suppressor Protein p53
Proto-Oncogene Proteins c-myc
MYC protein, human
TP53 protein, human